ABBVIE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?
ABBVIE has one hundred and thirty-nine approved drugs.
There are two hundred and thirty US patents protecting ABBVIE drugs.
There are two thousand seven hundred and thirty patent family members on ABBVIE drugs in sixty-six countries and three hundred and ninety-five supplementary protection certificates in nineteen countries.
Summary for ABBVIE
International Patents: | 2730 |
US Patents: | 230 |
Tradenames: | 125 |
Ingredients: | 99 |
NDAs: | 139 |
Drug Master File Entries: | 1 |
Patent Litigation for ABBVIE: | See patent lawsuits for ABBVIE |
Drugs and US Patents for ABBVIE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | RX | Yes | Yes | 7,056,927 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020517-003 | Jun 17, 2011 | RX | Yes | Yes | 8,921,326 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | 11,413,282 | ⤷ Sign Up | ⤷ Sign Up | ||||
Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-004 | Jul 18, 2016 | AB | RX | Yes | No | 8,283,379*PED | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ABBVIE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | LEXAPRO | escitalopram oxalate | TABLET;ORAL | 021323-002 | Aug 14, 2002 | 7,420,069*PED | ⤷ Sign Up |
Abbvie | ZEMPLAR | paricalcitol | SOLUTION;INTRAVENOUS | 020819-003 | Feb 1, 2000 | 6,136,799*PED | ⤷ Sign Up |
Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-003 | Jan 25, 2017 | 7,371,727 | ⤷ Sign Up |
Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-002 | Oct 22, 1996 | 5,721,244 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 800 mg | ➤ Subscribe | 2011-07-13 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg | ➤ Subscribe | 2013-06-10 |
➤ Subscribe | Ophthalmic Solution | 0.40% | ➤ Subscribe | 2005-01-28 |
➤ Subscribe | Tablets | 10 mg, 20 mg, and 40 mg | ➤ Subscribe | 2015-01-21 |
➤ Subscribe | Extended-release Tablets | 250 mg | ➤ Subscribe | 2004-05-03 |
➤ Subscribe | Capsules | 21 mg/10 mg | ➤ Subscribe | 2016-09-23 |
➤ Subscribe | Opthalmic Solution | 0.45% | ➤ Subscribe | 2011-08-24 |
➤ Subscribe | Extended-release Tablets | 7.5 mg and 15 mg | ➤ Subscribe | 2008-12-22 |
➤ Subscribe | Tablets | 100 mg/25 mg | ➤ Subscribe | 2008-12-23 |
➤ Subscribe | Ophthalmic Solution | 0.15% | ➤ Subscribe | 2006-11-03 |
➤ Subscribe | Extended-release Tablets | 1 mg/240 mg | ➤ Subscribe | 2008-02-20 |
➤ Subscribe | Capsules | 145 mcg and 290 mcg | ➤ Subscribe | 2016-08-30 |
➤ Subscribe | Ophthalmic Solution | 0.25% | ➤ Subscribe | 2014-07-30 |
➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Tablets | 5 mg/80 mg | ➤ Subscribe | 2017-06-09 |
➤ Subscribe | Ophthalmic Solution | 0.01% | ➤ Subscribe | 2011-04-05 |
➤ Subscribe | Delayed-release Capsules | 400 mg | ➤ Subscribe | 2014-06-17 |
➤ Subscribe | Capsules | 1 mcg and 2 mcg | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Topical Solution | 0.03% | ➤ Subscribe | 2010-05-03 |
➤ Subscribe | Delayed-release Capsules | 135 mg | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Gel | 7.5% | ➤ Subscribe | 2017-02-13 |
➤ Subscribe | Tablets | 400 mg and 600 mg | ➤ Subscribe | 2010-05-10 |
➤ Subscribe | Capsules | 10 mg and 20 mg | ➤ Subscribe | 2005-03-30 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg | ➤ Subscribe | 2013-08-16 |
➤ Subscribe | Injection | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | ➤ Subscribe | 2009-08-04 |
➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
➤ Subscribe | Suppository | 1000 mg | ➤ Subscribe | 2013-05-24 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg | ➤ Subscribe | 2013-06-17 |
➤ Subscribe | Injection | 400 mg/vial and 600 mg/vial | ➤ Subscribe | 2014-10-29 |
➤ Subscribe | Tablets | 5 mg/200 mg | ➤ Subscribe | 2005-05-27 |
➤ Subscribe | Extended-release Tablet | 500 mg | ➤ Subscribe | 2010-12-06 |
➤ Subscribe | Capsules | 14 mg/10 mg and 28 mg/10 mg | ➤ Subscribe | 2015-05-18 |
➤ Subscribe | Opthalmic Solution | 0.45% | ➤ Subscribe | 2011-08-23 |
➤ Subscribe | Extended-release Tablets | 500 mg | ➤ Subscribe | 2005-02-08 |
➤ Subscribe | Capsules | 7 mg/10 mg | ➤ Subscribe | 2016-09-26 |
➤ Subscribe | Ophthalmic Solution | 0.10% | ➤ Subscribe | 2006-12-20 |
➤ Subscribe | Extended-release Tablets | 2 mg/180 mg and 2 mg/240 mg | ➤ Subscribe | 2007-11-09 |
➤ Subscribe | Oral Solution | 80 mg/20 mg per mL | ➤ Subscribe | 2014-06-19 |
➤ Subscribe | Ophthalmic Solution | 0.2%/0.5% | ➤ Subscribe | 2008-11-21 |
➤ Subscribe | Extended-release Tablets | 4 mg/ 240 mg | ➤ Subscribe | 2007-07-24 |
➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
➤ Subscribe | Ophthalmic Solution | 0.03% | ➤ Subscribe | 2008-12-22 |
➤ Subscribe | Injection | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Tablets | 1 mg, 2 mg and 4 mg | ➤ Subscribe | 2004-10-04 |
➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2010-12-07 |
➤ Subscribe | Delayed-release Capsules | 45 mg | ➤ Subscribe | 2009-09-02 |
➤ Subscribe | Capsules | 4 mcg | ➤ Subscribe | 2008-08-25 |
➤ Subscribe | Tablets | 12.5 mg, 25 mg, 50 mg, and 100 mg | ➤ Subscribe | 2013-01-14 |
➤ Subscribe | Capsules | 5 mg | ➤ Subscribe | 2005-08-17 |
➤ Subscribe | Extended-release Capsules | 20 mg, 40 mg, 80 mg and 120 mg | ➤ Subscribe | 2017-07-25 |
➤ Subscribe | Gel | 10% | ➤ Subscribe | 2014-06-19 |
➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
➤ Subscribe | Injection | 10 mg/mL (2 mL) | ➤ Subscribe | 2018-07-13 |
➤ Subscribe | Extended-release Capsules | 28 mg | ➤ Subscribe | 2013-06-12 |
➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2009-08-12 |
➤ Subscribe | Tablets | 2.5 mg/200 mg | ➤ Subscribe | 2006-02-24 |
International Patents for ABBVIE Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2018104469 | ⤷ Sign Up |
Japan | 5060295 | ⤷ Sign Up |
South Korea | 20130064740 | ⤷ Sign Up |
European Patent Office | 1928446 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ABBVIE Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2340029 | 1590012-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119 |
1043327 | 92134 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CEFTAROLINE FOSAMIL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (ZINFORO) |
2638042 | CR 2023 00033 | Denmark | ⤷ Sign Up | PRODUCT NAME: ATOGEPANT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/23/1750 20230814 |
3692995 | 301229 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DEOXYCHOLAAT; NATIONAL REGISTRATION NO/DATE: RVG120593 20170804; FIRST REGISTRATION: IS IS/1/16/071/01 20160729 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.